The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
A Phase II Trial of Tideglusib in Alzheimer's Disease
Abstract
BACKGROUND: The ARGO study was a phase II, double-blind, placebo controlled, four parallel arm trial of tideglusib in Alzheimer's disease (AD). OBJECTIVE: To prove the clinical efficacy of an inhibitor of glycogen synthase kinase-3 (GSK-3), in AD. METHODS: Mild to moderate (Mini-Mental State Examination (MMSE) score, 14-26) AD patients on cholinesterase inhibitor and/or memantine treatment were administered tideglusib or placebo for 26 weeks. The ADAS-cog15 was the primary efficacy measure; function, cognition, behavior, and quality of life were assessed as secondary measures; cerebral atrophy in MRI and the levels of tau, amyloid-β, and BACE1 in cerebrospinal fluid (CSF) were exploratory endpoints. RESULTS: 306 AD patients were randomized to active (1000 mg QD: n = 86, 1000 mg QOD: n = 90, and 500 mg QD: n = 50) or placebo (n = 85) in 55 sites in four European countries. There were no statistically significant differences between either active and placebo arms in the efficacy variables. However, BACE1 in CSF significantly decreased with treatment in a small subgroup of patients. Participants with mild AD in the 500 mg QD group showed significant responses on ADAS-cog15, MMSE, and word fluency. Diarrhea (14-18% in active, 11% placebo) and dose-dependent, mild to moderate, and fully reversible transaminase increase (9-16% in active, 3.5% placebo) were the most frequent adverse events. CONCLUSIONS: Short term (26 weeks) tideglusib was acceptably safe but produced no clinical benefit in this trial. However, given the non-linear dose response, especially in mildly affected patients, further dose finding studies in early disease stages and for longer duration are warranted to examine GSK-3 inhibition in AD patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, use of tau kinase inhibitors such as the GSK-3 inhibitor Tideglusib to attenuate pathological tau hyperphosphorylation also showed little or no efficacy in Phase 2 trials, probably due to the critical role of GSK-3 in multifunctional signaling pathways [650, 651].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [650]
In the citing paper
“Moreover, use of tau kinase inhibitors such as the GSK-3 inhibitor Tideglusib to attenuate pathological tau hyperphosphorylation also showed little or no efficacy in Phase 2 trials, probably due to the critical role of GSK-3 in multifunctional signaling pathways [650, 651].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [650]
In the citing paper
“The clinical studies in patients with mild-to-moderate AD (NCT01350362, NCT00948259) or PSP (NCT01049399) patients treated with tideglusib were negative on the clinical outcomes [218]; however, a subgroup analysis of PSP patients showed reduced brain atrophy [219].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [218]
In the citing paper
“However, a phase 2 trial in mild to moderate AD did not demonstrate any reduction in rate of cognitive or functional decline as compared to placebo (Lovestone et al., 2015)”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Lovestone et al., 2015
In the citing paper
“Tideglusib, a small-molecule GSK3β inhibitor, failed to improve cognition in a phase 2 clinical study, and CSF levels of Aβ42, total tau, and pTau181 were not altered, resulting in failure of the trial [175,176].”
From Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review (2024) · cites this paper as [176]
In the citing paper
“In a larger phase II study, tideglusib treatment was associated with significant cognitive improvement and a reduction in CSF levels of β-secretase in a subgroup of patients with mild AD122. However, when the entire study cohort was analysed, tideglusib was found to be well tolerated but produced no significant improvements122.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [122]
In the citing paper
“Another GSK-3 inhibitor, tideglusib, did not meet phase 2 clinical endpoints in patients with mild and moderate AD.80”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [80]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347
A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
Wahlund, L., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjögren, M., Wallin, A., Adèr, H., Leys, D., Pantoni, L., et al. (2001) · Stroke · doi:10.1161/01.str.32.6.1318 · Cited by 1,838
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
The glamour and gloom of glycogen synthase kinase-3
Jope, R. S., & Johnson, G. V. W. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.12.004 · Cited by 1,535
Guy, W. L. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,441
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 556
Human SPG11 cerebral organoids reveal cortical neurogenesis impairment
Pérez‐Brangulí, F., Buchsbaum, I. Y., Pozner, T., Regensburger, M., Fan, W., Schray, A., Boerstler, T., Mishra, H., Gräf, D., Kohl, Z., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy397 · Cited by 38
Alzheimer’s Disease-Related Epigenetic Changes: Novel Therapeutic Targets
Paniri, A., Hosseini, M. M., & Akhavan‐Niaki, H. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03626-y · Cited by 34
New insights into glycogen synthase kinase-3: A common target for neurodegenerative diseases
Wang, C., Cui, Y., Xu, T., Zhou, Y., Wang, T., & Wang, T. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115923 · Cited by 31
A glimpse into novel acylations and their emerging role in regulating cancer metastasis
Shi, H., Cui, W., Qin, Y., Chen, L., Yu, T., & Lv, J. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05104-z · Cited by 35
Karati, D., Meur, S., Roy, S., Mukherjee, S., Debnath, B., Jha, S. K., Sarkar, B. K., Naskar, S., & Ghosh, P. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03500-1 · Cited by 31
Pathogenic Feed-Forward Mechanisms in Alzheimer’s and Parkinson’s Disease Converge on GSK-3
Albeely, A. M., Ryan, S. D., & Perreault, M. L. (2018) · Brain Plasticity · doi:10.3233/bpl-180078 · Cited by 33
Alpan, A. L., Çalışır, M., Kızıldağ, A., Özdede, M., & Özmen, Ö. (2020) · Journal of Craniofacial Surgery · doi:10.1097/scs.0000000000006326 · Cited by 33
Stojakovic, A., Chang, S.-Y., Nesbitt, J. J., Pichurin, N. P., Ostroot, M., Aikawa, T., Kanekiyo, T., & Trushina, E. V. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-201015 · Cited by 31
G protein‐coupled receptor kinases are associated with Alzheimer's disease pathology
Guimarães, T. R., Swanson, E., Kofler, J., & Thathiah, A. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12742 · Cited by 31
Understanding Glycogen Synthase Kinase-3: A Novel Avenue for Alzheimer’s Disease
Sequeira, R. C., & Godad, A. P. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03839-1 · Cited by 31
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 32
Lajarín-Cuesta, R., Nanclares, C., Arranz-Tagarro, J.-A., González‐Lafuente, L., Arribas, R. L., de Brito, M. A., Gandı́a, L., & Rı́os, C. D. L. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00478 · Cited by 30
van der Vaart, A. D., Meng, X., Bowers, M. S., Batman, A. M., Alıev, F., Farris, S. P., Hill, J., Green, T. A., Dick, D. M., Wolstenholme, J. T., et al. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0202-x · Cited by 30
GSK-3β Allosteric Inhibition: A Dead End or a New Pharmacological Frontier?
Balboni, B., Masi, M., Rocchia, W., Girotto, S., & Cavalli, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087541 · Cited by 30
The role of PI3K/AKT pathway and its therapeutic possibility in Alzheimer's disease
Yu, H.-J., & Koh, S. (2017) · Hanyang Medical Reviews · doi:10.7599/hmr.2017.37.1.18 · Cited by 30
GSK-3 Inhibitors: A Double-Edged Sword? – An Update on Tideglusib
Mathuram, T. L., Reece, L. M., & Cherian, K. M. (2018) · Drug Research · doi:10.1055/s-0044-100186 · Cited by 30
Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets
Herman, F. J., Simkovic, S. J., & Pasinetti, G. M. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14569 · Cited by 29
Cai, N., Chen, J., Bi, D., Gu, L., Yao, L., Li, X., Li, H., Xu, H. Y., Hu, Z., Liu, Q., et al. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b07022 · Cited by 29
Treatment of epilepsy for people with Alzheimer's disease
Liu, J., & Wang, L. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011922.pub4 · Cited by 29
Baruah, J., Hitzman, R. T., Zhang, J., Chaudhuri, S., Mastej, V., & Wary, K. K. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.814376 · Cited by 29
Zhao, Z., Yuan, Y., Li, S., Wang, X., & Yang, X. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14885 · Cited by 28
Alfei, S., & Zuccari, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020844 · Cited by 28
Perspectives on the Clinical Development of NRF2-Targeting Drugs
Lastra, D., Fernández-Ginés, R., Manda, G., & Cuadrado, A. (2020) · Handbook of experimental pharmacology · doi:10.1007/164_2020_381 · Cited by 29
Holzer, M., Schade, N., Opitz, A., Hilbrich, I., Stieler, J., Vogel, T., Neukel, V., Oberstadt, M., Totzke, F., Schächtele, C., et al. (2018) · Molecules · doi:10.3390/molecules23092335 · Cited by 28
Duggal, P., & Mehan, S. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190125 · Cited by 28
Gowda, C. S., Soliman, M., Kapadia, M. A., Ding, Y., Payne, K. J., & Dovat, S. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.06.001 · Cited by 30
Boulebd, H., Ismaïli, L., Bartolini, M., Bouraiou, A., Andrisano, V., Martin, H., Bonet, A., Moraleda, I., Iriepa, I., Chioua, M., et al. (2016) · Molecules · doi:10.3390/molecules21040400 · Cited by 27
Kinase Targets in Cns Drug Discovery
Gunosewoyo, H., Yu, L.-F., Munoz, L., & Kassiou, M. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0214 · Cited by 27
A mathematical model of multisite phosphorylation of tau protein
Stepanov, A. A., Karelina, T., Markevich, N. I., Demin, O. O., & Nicholas, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192519 · Cited by 26
Kuo, Y., & Rajesh, R. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1621750 · Cited by 27
Evaluating a New Class of AKT/mTOR Activators for HIV Latency-Reversing Activity Ex Vivo and In Vivo
Gramatica, A., Schwarzer, R., Brantley, W., Varco-Merth, B. D., Sperber, H. S., Hull, P. A., Montaño, M., Migueles, S. A., Nettere, D., Hogan, L. E., et al. (2021) · Journal of Virology · doi:10.1128/jvi.02393-20 · Cited by 27
Gutti, G., Leifeld, J., Ramakrishna, K., Bajad, N. G., Ganeshpurkar, A., Kumar, A., Krishnamurthy, S., Klein-Schmidt, C., Tapken, D., Hollmann, M., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115670 · Cited by 26
Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT
Declercq, L., Vandenberghe, R. R., Laere, K. V., Verbruggen, A., & Bormans, G. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00088 · Cited by 27
Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update
Khan, S. S., Khatik, G. L., & Datusalia, A. K. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411083922 · Cited by 25
Atila, D., Keskin, D. S., Lee, Y., Lin, F., Hasırcı, V., & Tezcaner, A. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.113078 · Cited by 25
Hartz, R. A., Ahuja, V. T., Luo, G., Chen, L., Sivaprakasam, P., Xiao, H., Krause, C., Clarke, W., Xu, S., Tokarski, J. S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00364 · Cited by 25
Glycogen synthase kinase-3: A potential immunotherapeutic target in tumor microenvironment
Liang, J., Yu, M., Li, Y., Zhao, L., & Wei, Q. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116377 · Cited by 25
A novel GSK-3 inhibitor binds to GSK-3β via a reversible, time and Cys-199-dependent mechanism
Ghazanfari, D., Noori, M. S., Bergmeier, S. C., Hines, J. V., McCall, K. D., & Goetz, D. J. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116179 · Cited by 25
Tau Protein-Targeted Therapies in Alzheimer’s Disease: Current State and Future Perspectives
Pluta, R. M., & Ułamek-Kozioł, M. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch4 · Cited by 27
Jin, Z., Lu, Y., Tang, H., & Cui, H. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70472 · Cited by 24
Davies, M. P., Benítez‐Fernández, R., Pérez, C., Jakupovic, S., Welsby, P. J., Rzepecka, K., Alder, J. E., Davidson, C., Martı́nez, A., & Hayes, J. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01568 · Cited by 23
Preservation of neurocognitive function in the treatment of brain metastases
Parsons, M. W., Peters, K. B., Floyd, S., Brown, P. D., & Wefel, J. S. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab122 · Cited by 23
Targeting Tau to Treat Clinical Features of Huntington's Disease
Masnata, M., Salem, S., Jacquet, A. D. R., Anwer, M., & Cicchetti, F. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.580732 · Cited by 25
Shukla, R., Kumar, A., Kelvin, D. J., & Singh, T. R. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1078987 · Cited by 22
Discovery of new GSK-3β inhibitors through structure-based virtual screening
Dou, X., Jiang, L., Wang, Y., Jin, H., Liu, Z., & Zhang, L. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.11.036 · Cited by 22
Zarini-Gakiye, E., Amini, J., Sanadgol, N., Vaezi, G., & Kazem, P. (2020) · Current Molecular Pharmacology · doi:10.2174/1874467213666200422090135 · Cited by 22
Alqahtani, S. M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Shokr, M. M., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-02000-9 · Cited by 21
Curcumin as a Holistic Treatment for Tau Pathology
Sivanantharajah, L., & Mudher, A. K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.903119 · Cited by 22
Tideglusib enhances odontogenic differentiation in human dental pulp stem cellsin vitro
Kornsuthisopon, C., Tompkins, K. A., & Osathanon, T. (2022) · International Endodontic Journal · doi:10.1111/iej.13877 · Cited by 21
Rostgaard, N., Jul, P., Garmer, M., & Volbracht, C. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2205135 · Cited by 21
Huang, H.-J., Chen, S.-L., & Hsieh‐Li, H. M. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00312 · Cited by 21
Wang, Z., Xiong, L., Wan, W., Duan, L., Bai, X., & Zu, H. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00032 · Cited by 22
Zhang, P., Min, Z., Gao, Y., Bian, J., Lin, X., He, J., Ye, D., Li, Y., Peng, C., Cheng, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02254 · Cited by 21
Wnt Signaling in the Adult Hippocampal Neurogenic Niche
Arredondo, S. B., Valenzuela-Bezanilla, D., Santibanez, S. H., & Varela‐Nallar, L. (2022) · Stem Cells · doi:10.1093/stmcls/sxac027 · Cited by 21
Zhang, J., Lv, W., Zhang, G., Zeng, M., Cao, W., Su, J., Cao, K. J., & Liu, J. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0339 · Cited by 22
Dual-target inhibitors of cholinesterase and GSK-3β to modulate Alzheimer’s disease
He, J., & Tam, K. Y. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103914 · Cited by 20
Drug Repurposing in Dentistry: Towards Application of Small Molecules in Dentin Repair
Birjandi, A. A., Suzano, F. R., & Sharpe, P. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176394 · Cited by 20
Nozal, V., García‐Rubia, A., Cuevas, E. P., Pérez, C., Tosat‐Bitrián, C., Bartolomé, F. B., Carro, E., Ramírez, D., Palomo, V., & Martı́nez, A. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202106295 · Cited by 20
Silva, G. M., Borges, R. S., Santos, K. L. B., Federico, L. B., Francischini, I. A. G., Gomes, S. Q., Barcelos, M. P., Silva, R. C., Santos, C. B. R., & da Silva, C. H. T. D. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158252 · Cited by 20
Rao, A. C., Venkatesh, K. V., Nandini, V., Sihivahanan, D., Alamoudi, A. A., Bahammam, H. A., Bahammam, S. A., Zidane, B., Bahammam, M. A., Chohan, H., et al. (2022) · Materials · doi:10.3390/ma15134567 · Cited by 19
Hanna, S., Aly, R. M., Eldeen, G. N., Velasco, A. A., & Alfayate, R. P. (2023) · Biomedicines · doi:10.3390/biomedicines11020542 · Cited by 19
Protein aggregation and neurodegenerative disease: Structural outlook for the novel therapeutics
Arar, S. H., Haque, M. A., & Kayed, R. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26561 · Cited by 20
Kofoed, R. H., Betzer, C., Ferreira, N., & Jensen, P. H. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104720 · Cited by 19
Inhibition of hippocampal long-term potentiation by high-fat diets
Contreras, A., Rio, D. D., Martı́nez, A., Gil, C., Morales, L., Ruiz‐Gayo, M., & Olmo, N. D. (2017) · Neuroreport · doi:10.1097/wnr.0000000000000774 · Cited by 20
Vohwinkel, C. U., Buchäckert, Y., Al-tamari, H. M., Mazzocchi, L. C., Eltzschig, H. K., Mayer, K., Morty, R. E., Herold, S., Seeger, W., Pullamsetti, S. S., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0358oc · Cited by 19
Unleashing β-catenin with a new anti-Alzheimer drug for bone tissue regeneration
Comeau‐Gauthier, M., Tarchala, M., Ramírez-GarcíaLuna, J. L., Harvey, E. J., & Merle, G. E. (2020) · Injury · doi:10.1016/j.injury.2020.07.035 · Cited by 20
Xu, Y., Zheng, F., Zhong, Q., & Zhu, Y. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230002 · Cited by 20
Targets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 18
Swinney, Z., Haubrich, B. A., Xia, S., Ramesha, C. S., Gomez, S. R., Guyett, P. J., Mensa‐Wilmot, K., & Swinney, D. C. (2016) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0004506 · Cited by 18
Huang, H.-J., Chen, S.-L., Huang, H., Sun, Y., Lee, G.-C., Lee‐Chen, G., Hsieh‐Li, H. M., & Su, M. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5108-0 · Cited by 18
Bou-Gharios, J., Assi, S., Bahmad, H. F., Kharroubi, H., Araji, T., Chalhoub, R., Ballout, F., Harati, H., Fares, Y., & Abou-Kheir, W. G. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00180-5 · Cited by 18
Rico, A., Guembelzu, G., Palomo, V., Martı́nez, A., Aiastui, A., Casas-Fraile, L., Valls, A., de Munaín, A. L., & Sáenz, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147367 · Cited by 17
Chuang, W.-H., Chou, Y.-T., Chen, Y.-H., Kuo, T.-H., Liaw, W., Lu, T., Kao, C.-F., & Wang, Y. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00348 · Cited by 17
Rahimi, A., Sameei, P., Mousavi, S., Ghaderi, K., Hassani, A., Hassani, S., & Alipour, S. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04143-2 · Cited by 18
Gao, Y., Zhang, P., Cui, A., Ye, D., Xiang, M., & Chu, Y. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.09.027 · Cited by 17
Glycogen Synthase Kinase 3β Enhances Hepatitis C Virus Replication by Supporting miR-122
Saleh, M., Rüschenbaum, S., Welsch, C., Zeuzem, S., Moradpour, D., Gouttenoire, J., & Lange, C. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02949 · Cited by 17
Chi, H., Lee, S., Shiu, R.-H., Han, R., Hsieh, C.-P., Wei, T.-M., Lo, C., Chang, H.-Y., & Sang, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-70423-1 · Cited by 17
Wu, F., Li, W., Lu, H., & Li, L. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101003 · Cited by 16
Emerging trends of injectable hydrogels for vital pulp therapy: A comprehensive review
Islam, M. R. R., Islam, R., Sano, H., Toida, Y., Hoshika, S., Ahmed, H. M. A., & Tomokiyo, A. (2025) · International Endodontic Journal · doi:10.1111/iej.14279 · Cited by 16
Góral, I., Wichur, T., Sługocka, E., Grygier, P., Głuch‐Lutwin, M., Mordyl, B., Honkisz-Orzechowska, E., Szałaj, N., Godyń, J., Panek, D., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00365 · Cited by 17
Stem cell therapy in Alzheimer’s disease: current status and perspectives
Ou, C.-M., Xue, W.-W., Liu, D., Ma, L., Xie, H.-T., & Ning, K. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1440334 · Cited by 16
Pomeislová, A., Otmar, M., Rubešová, P., Benýšek, J., Matoušová, M., Mertlíková‐Kaiserová, H., Pohl, R., Slavětínská, L. P., Pomeisl, K., & Krečmerová, M. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.115998 · Cited by 16
The Development of Pharmacological Therapies for Alzheimer’s Disease
Ping, L., Sun, J., Cheng, Q., Yang, Y., Cordato, D. J., & Gao, J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00282-z · Cited by 16
Blood-Based Kinase Assessments in Alzheimer’s Disease
Hugon, J., Mouton‐Liger, F., Cognat, E., Dumurgier, J., & Paquet, C. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00338 · Cited by 16
Unlocking hope: GSK-3 inhibitors and Wnt pathway activation in Alzheimer’s therapy
Varshini, M. S., Reddy, R. A., & Krishnamurthy, P. T. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2365263 · Cited by 15
The Role of Kinases in Neurodegenerative Diseases: From Pathogenesis to Treatment
Naim, A., Farooqui, A. M., Badruddeen, B., Khan, M. I., Akhtar, J., Ahmad, A., & Islam, A. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70156 · Cited by 15
Thornton, T. M., Hare, B. D., Colié, S., Pendlebury, W. W., Nebreda, Á. R., Falls, W. A., Jaworski, D. M., & Rincón, M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.187 · Cited by 16
Mota, B. C., Ashburner, N., Abelleira, L. E., Liu, L., Aleksynas, R., Rovati, L. C., Caselli, G., & Sastre, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137320 · Cited by 15
Lin, C., Hsieh, Y.-S., Sun, Y., Huang, W., Chen, S., Weng, Z.-K., Lin, T., Wu, Y., Chang, K., Huang, H., et al. (2022) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2022.035 · Cited by 15
Manoharan, S. D., Hamid, H. A., Hashim, N. F. M., Cheema, M. S., Chiroma, S. M., Mustapha, M., & Mehat, M. Z. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148793 · Cited by 14
Li, J., Zhang, Y., Tang, R., Liu, H., Li, X., Lei, W., Chen, J., Jin, Z., Tang, J., Wang, Z., et al. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31335 · Cited by 15
Advances of therapy for Alzheimer's disease: An updated review
Mei, C., Zhan, J., Zhu, S., Zhang, Y., Xiong, C., Wang, J., Xu, Y. J., Zhong, H., & Cheng, J. (2024) · Brain‐X · doi:10.1002/brx2.68 · Cited by 15
Treatment of epilepsy for people with Alzheimer's disease
Liu, J., Wang, L., Wu, L., & Wang, Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011922.pub3 · Cited by 14
Probiotic supplement as a promising strategy in early tau pathology prevention: Focusing on GSK-3β?
Flynn, C. M., & Yuan, Q. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1159314 · Cited by 15
Daouk, R., Hassane, M., Bahmad, H. F., Sinjab, A. F., Fujimoto, J., Abou-Kheir, W. G., & Kadara, H. N. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00207 · Cited by 14
Zaman, A., Drake, S., & Fournier, A. E. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70323 · Cited by 14
Molecular Insights into Tau Pathology and its Therapeutic Strategies in Alzheimer's Disease
Zhou, F., Zhao, Y., Sun, Y., & Chen, W. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2311197 · Cited by 13
Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies
Uliassi, E., Bolognesi, M. L., & Milelli, A. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00733 · Cited by 13
Piazzi, M., Bavelloni, A., Faenza, I., & Blalock, W. L. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118769 · Cited by 13
Jankowska, A., Wesołowska, A., Pawłowski, M., & Chłoń‐Rzepa, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190620095623 · Cited by 13
Metadata
- Authors
- Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., León, T., & del Ser, T.
- Affiliations
- University of Oxford (GB)
- Fundació ACE (ES)
- Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain
- Inserm (FR)
- University of Turku (FI)
- Instituto de Salud Carlos III (ES)
- Clinical Department, Noscira SA, Madrid, Spain
- Medical Department, Noscira SA, Madrid, Spain
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2015-03-03
- Volume
- 45
- Issue
- 1
- Pages
- 75-88
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1522284801
- Cited by
- 536
- References
- 47
- Citations by year
- 2026: 44 · 2025: 67 · 2024: 59 · 2023: 46 · 2022: 38 · 2021: 59 · 2020: 61 · 2019: 31 · 2018: 46 · 2017: 39 · 2016: 31 · 2015: 14
- FWCI
- 32.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0512-10053)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- tideglusib, Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Dose-Response Relationship, Drug, Double-Blind Method, Enzyme-Linked Immunosorbent Assay, Female, Follow-Up Studies, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Thiadiazoles, Amyloid beta-Peptides, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
